bioAffinity’s siRNA Therapy Shows Selective Skin Cancer Cell Kill in Preclinical Study
Event summary
- bioAffinity’s proprietary siRNA therapy demonstrated selective cytotoxicity to squamous and basal skin cancer cells in vitro while sparing healthy cells.
- The findings will be presented at the RNATx Symposium on June 24-26, 2026.
- The research builds on earlier discoveries targeting CD320 and LRP2 receptors, patented in 2025 (U.S. Patent No. 12,305,171).
- No human trials have been conducted; preclinical results require further validation.
The big picture
bioAffinity’s findings contribute to the growing field of RNA therapeutics, particularly for non-melanoma skin cancers, which affect millions annually. The company is leveraging its expertise in diagnostics (e.g., CyPath® Lung) to expand into targeted oncology treatments, a strategic shift that could diversify its revenue streams if preclinical success translates clinically.
What we're watching
- Clinical Translation Risk
- Whether in vitro selectivity will translate to human trials, given the historical challenges of siRNA therapies.
- Regulatory Pathway
- The pace at which bioAffinity can secure FDA approval for an IND application and advance into clinical testing.
- Competitive Positioning
- How this technology differentiates from existing topical treatments or emerging RNA-based cancer therapies in development.
Related topics